| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19167SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50037SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24915SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33130 | |||
| IHC-Prediluted | NBP2-45339 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-46892SS | |||
| Azide and BSA Free | NBP2-80829 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27416 | |||
| BSA Free | NB100-56712SS | |||
| Azide and BSA Free | NBP2-27416SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1596SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56112SS | |||
![Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Western-Blot-NB100-513-img0004.jpg "Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds")
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of human ovarian carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0002.jpg)
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of mouse renal cell carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0001.jpg)
![Immunoprecipitation: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Immunoprecipitation-NB100-513-img0003.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.](http://images.novusbio.com/fullsize/LC3A-Antibody-Western-Blot-NBP1-19167-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LC3A Antibody [NBP1-19167] - LC3/MAP1 [NBP1-19167] - LC3 antibody was tested in HeLa cells with Dylight 488 (green). Cells were treated overnight with 50 uM chloroquine to induce autophagosome formation. Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19167-img0013.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse brain using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the cells with highest positivity in various neurons.](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0014.jpg)
![Western Blot: LC3/MAP1LC3A Antibody [NBP1-19167] - Human brain lysate.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Western-Blot-NBP1-19167-img0004.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse liver using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the hepatocytes and other liver cells.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0010.jpg)
![Simple Western: LC3A Antibody [NBP1-19167] - Image shows a specific band for LC3 in 0.5 mg/mL of Neuro2A lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Simple-Western-NBP1-19167-img0009.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Section of rat hippocampus stained with mouse monoclonal antibody to c-FOS NBP2-50037 in red and counterstained with rabbit polyclonal antibody to FOX3/NeuN. DAPI reveals nuclei of neurons and glia in blue. The hippocampal neurons stain green for FOX3/NeuN and a few also are expressing c-FOS, and so appear orange. These cells were spontaneously active at the time the animal was sacrificed.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and c-Fox knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Mouse Anti-Human c-Fox Monoclonal Antibody (Catalog # NBP2-50037) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for c-Fox at approximately 52 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Knockout-Validated-NBP2-50037-img0005.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Analysis of cell lysates using mouse c-Fos mAb, dilution 1:1,000 (Green), and rabbit GAPDH pAb, dilution 1:20,000 (Red) used as a loading control. [1] protein standard (red), [2] HeLa cells in serum free media. [3] HeLa cells stimulated with 20% fetal bovine serum for 2hrs after 36hrs in serum free media. [4] rat cortical neurons. [5] rat cortical neurons treated with membrane depolarization buffer for 5hrs. Multiple bands at 50-65kDa in stimulated or treated cell lysates correspond to different forms of the c-Fos proten. The single band at 37 kDa represents GAPDH protein.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0007.jpg)
![Immunohistochemistry: c-Fos Antibody (2H2) [NBP2-50037] - pAb 1:1000 (green), DAPI counterstain (blue) on 30 micron cryosection of mouse spinal cord. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-NBP2-50037-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Left: NBP2-50037 staining (green) in HeLa cells, which were treated with serum-starvation for 36 hrs, followed by 2 hrs 20% FBS stimulation (bottom), or PBS treatment (top). Green c-Fos staining only localizes in the nuclei of stimulated cells, but not in un-stimulated cells. Cells are counter-stained with chicken pAb against Vimentin (NB300-223, red). Blue shows DAPI staining of nucleus. Middle: Mouse brain section (45 uM; fixed by transcardial perfusion with 4% PFA) labeled with NBP2-50037 using a standard HRP-DAB staining technique. Cells expressing c-Fos show dark color in nucleus. Right: Mouse cortical section labeled with NBP2-50037 (red) and rabbit polyclonal anti-NeuN (NBP1-92716, green) using IF confocal. Neurons positive for c-Fos and RBFOX3/NeuN appear to be yellow. Inset shows an enlarged image of NBP2-50037 staining. Nuclei are labeled with Dapi (blue).](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0001.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Bovine ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0006.jpg "Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Bovine ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Analysis of Superoxide Dismutase 1 in FFPE human liver tissue using an isotype control (top) and NBP2-24915 (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Immunohistochemistry-Paraffin-NBP2-24915-img0003.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Analysis of SOD in liver lysate of 1) human, 2) mouse, and 3) rat using this antibody. 025 ug/ml.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0004.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Human ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0005.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Western-Blot-NB600-1160-img0013.jpg "Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)")
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Immunofluorescence Analysis of T98G cells labeling Pgp9.5 with UCH-L1/PGP9.5 Antibody (31A3) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Nucspot (Red)](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunocytochemistry-Immunofluorescence-NB600-1160-img0012.jpg)
![Immunohistochemistry-Paraffin: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Formalin-fixed, paraffin-embedded human brain stained with UchL1 antibody (PGP9.5) (1:500), peroxidase-conjugate and DAB chromogen. Staining seen in cytoplasm, ER and membrane. Fixation in 95% ethanol/5% acetic acid for 2-3 hours prior to paraffin embedding is recommended. Specimens which have not been fixed in acetic acid/alcohol require pre-treatment with citrate buffer: for example, unmask of the target epitope by boiling the tissue sections in 10mM citrate buffer, pH 6.0, for 10 min followed by cooling at room temp for 20 min.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunohistochemistry-Paraffin-NB600-1160-img0004.jpg)
![Flow Cytometry: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Flow Cytometric Analysis of T98G cells using UCH-L1/PGP9.5 Antibody (31A3)followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Flow-Cytometry-NB600-1160-img0011.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of UchL1 in 1) human, 2) mouse and 3) rat brain lysate using UchL1 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Western-Blot-NB600-1160-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of PGP9.5 in rat mesenteric artery using anti-PGP9.5 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunocytochemistry-Immunofluorescence-NB600-1160-img0005.jpg)
![Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Simple Western lane view shows a specific band for PGP9.5 / UCHL-1 in 0.2 mg/ml of h. Cerebellum (left) and IMR-32 (right) lysate(s). This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Simple-Western-NB600-1160-img0006.jpg)
![Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Electropherogram images of the corresponding Simple Western lane. PGP9.5 / UCHL-1 antibody was used at 10 ug/ml dilution of h. Cerebellum and IMR-32 lysates(s) respectively.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Simple-Western-NB600-1160-img0010.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0028.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - LC3B was detected in immersion fixed Chloroquine treated Hela cells (left) but was not detected in LC3B knockout Hela cells (right) using rabbit anti-human LC3B monoclonal antibody (1251A) [Catalog #NBP2-46892] at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0036.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - The expression of LC3B in rat tissue. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0034.jpg)
![<b>Biological Strategies Validation. </b>Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - Jurkat cells were either untreated (A) or treated with 50uM chloroquine for 24 hours (B). An intracellular stain was performed with anti-LC3B (1251A) antibody [Catalog # NBP2-46892] (blue) and a matched isotype control [Catalog # MAB1050] (orange). Cells were fixed with 4% paraformaldehyde, following fixation, cells were permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by rabbit IgG APC-conjugated secondary antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Effects of PDTC on LC3 on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level and given in relative arbitrary units. LC3-II increased in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II compared with vehicle-treated rats. Data were expressed as mean +/- SEM, n = 6/group. *P < 0.05 vs sham-operated group. # P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation and puncture. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26067996) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with Chloroquine for 24 hours prior to fixation, permeabilization and incubation with anti- [Catalog # NBP2-46892] and anti tubulin (NB100-690) antibodies. Image enlargement shows the accumulation of LC3 (green) on autophagosomes in response to Chloroquine treatment. Tubulin staining is shown in red and DNA is counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0032.jpg)
![Immunohistochemistry-Paraffin: LC3B Antibody (1251A) [NBP2-46892] - IHC (Immunohistochemical) analysis of a formalin fixed and paraffin embedded tissue section of normal mouse brain using rabbit monoclonal LC3B (1251A) antibody [Catalog # NBP2-46892] at 1:100 dilution with HRP-DAB detection. The antibody generated a weak diffused cytoplasmic staining in most of the cells but some cells, especially within empty areas on the section, showed punctate signal also which signifies the presence of autophagy in those areas.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunohistochemistry-Paraffin-NBP2-46892-img0033.jpg)
![Flow Cytometry: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells untreated or treated with 50 uM chloroquine for 24h. Image from the Alexa Fluor 405 version of this antibody.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Cytometry-NBP2-46892-img0037.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Analysis shows lysates of HeLa human cervical epithelial carcinoma cell line untreated (-) or treated (+) with Chloroquine. PVDF membrane was probed with 0.2 ug/mL rabbit anti-LC3B monoclonal Antibody (1251A) (Catalog # NBP2-46892, Novus Biologicals), followed by 1:2000 dilution of goat anti-rabbit IgG secondary antibody. A specific band was detected for LC3B at a molecular weight of approximately 15 kDa in CQ treated NIH-3T3 and PC12 cell lines.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis using HeLa cells treated with (+) or without (-) Chloriquine (CQ). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot image of monoclonal anti-LC3B Antibody (Clone 1251D) [Catalog # NBP2-46892]. HeLa and Neuro2A cells were treated with or without 50 uM chloroquine for 24 hours as indicated. Whole cell protein was then separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane for 30 min and blocked in 5% non-fat milk in TBST (Tris-buffered saline, 0.1% Tween 20). The membrane was probed with 2 ug/ml anti-LC3B Antibody in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the accumulation of LC3B II upon chloroquine treatment. Bands for LC3 were detected at a molecular weight of approximately 15 kDa in treated HeLA cells, and both treated and untreated Neuro2A cells.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with 50 uM Chloroquine for 24 hour prior to fixation in 10% buffered formalin for 10 min. Cells were permeabilized in 0.1% Triton X-100 and incubated with 20 ug/ml anti- [Catalog # NBP2-46892] and 1:500 anti-tubulin [Catalog # NB100-690] for 1 h at room temperature. LC3B reactivity (green) was detected with ant-rabbit Dylight 488 and tubulin (red) with anti-mouse Dylight 550. Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0030.jpg)
![Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - HeLa human cervical epithelial carcimoa cell line either treated with 50 uM chloroquine for 24 hours (filled histogram) or untreated (open histogram) was stained with Rabbit anti-Human LC3B Alexa Fluor 647 conjugated monoclonal antiobdy (1251A) [Catalog # NBP2-46892AF647]. To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation and Permeabilization Buffer Kit (FC012-NOV).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0025.jpg)
![Immunoprecipitation: LC3B Antibody (1251A) [NBP2-46892] - Western blot analysis of LC3 immunoprecipitation. 10 ug of monoclonal anti-LC3B antibody (clone 1251A) [Catalog # NBP2-46892] was used to immunoprecipitate LC3 from 200 ug of total protein from HeLa cells treated with or without 50 uM chloroquine for 24 h. Antibody-protein was captured by magnetic protein A/G beads, washed and subjected to SDS-PAGE on a 4-15% gel. Protein was transferred to 0.2 um PVDF membrane and probed with 2 ug/ml anti-LC3B (NB100-2220) and detected with an anti-rabbit HRP conjugated secondary antibody using chemiluminescence. The detection of LC3 at a molecular weight of approximately 12 kDa and the antibody heavy chain (Ab Hc) at a molecular weight of approximately 50 kDa is indicated.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunoprecipitation-NBP2-46892-img0031.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - Effects of PDTC on LC3 (a), Beclin1 (b), LAMP-1 (c), & Rab7 (d) on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level & given in relative arbitrary units. LC3-II increased while Beclin1, Rab7, & LAMP-1 declined in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II, Beclin1, Rab7, & LAMP-1 compared with vehicle-treated rats. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. #P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-310202415291956.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - a LC3 in brains harvested 3, 6, 12, 24, & 48 h after CLP. b Immunofluorescence for LC3 in neurons after CLP injury. Values of protein data were related to signals obtained from actin protein & given as relative arbitrary units. LC3-II significantly increased in CLP rats at 6, 12, 24, & 48 h after surgery compared with sham-operated rats. Three-color staining for anti-LC3 antibody (green), NeuN (red), & DAPI (blue) showed that a staining pattern changes from largely diffuse to predominantly punctate & cytoplasmic in hippocampal neurons after CLP. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture, DAPI 4,6-diamidino-2-phenylindole Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-31020241612245.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0013.jpg "Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.")
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lane view shows a specific band for NFkB p65 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0006.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lysates of HeLa human cervical epithelial carcinoma cell line and Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 ug/mL mouse anti-RelA/NFkB p65 monoclonal (NB100-56712, Novus Biologicals), followed by 1:2000 dilution of the appropriate HRP-conjugated secondary antibody, donkey anti-mouse IgG (HAF018).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0016.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Ovarian cystadenocarcinoma probed with p65 antibody at 5 ug/mL. Human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Immunohistochemistry-Paraffin-NB100-56712-img0009.jpg)
![Flow Cytometry: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Intracellular staining of 293 HEK cells using 0.5 ug of p65 antibody. Green histogram represents the isotype control (p65) antibody. This NFkB p65 antibody was used for this test with an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Flow-Cytometry-NB100-56712-img0004.jpg)
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Detection of p65 by Simple Western (JESS) in chemiluminescence in nuclear extract of reconstructed human epidermis lysate (about 600 ug/mL protein concentration).Antibody at 1:20. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0017.jpg)
![Western Blot: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) and hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2017/3795950/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Aromatase-Antibody-Western-Blot-NB100-1596-img0005.jpg "Western Blot: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) and hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2017/3795950/), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Aromatase Antibody [NB100-1596] - U2OS cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Aromatase Antibody NB100-1596 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Aromatase-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1596-img0008.jpg)
![Immunohistochemistry-Paraffin: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control rabbits. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of control ovaries. Nonlabeling was observed when the primary antibody was omitted. Bars: 200 um (1st image) and 20 um (2nd image). Granulose cells, gc; theca cells, tc. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2017/3795950/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Aromatase-Antibody-Immunohistochemistry-Paraffin-NB100-1596-img0006.jpg)
![Western Blot: Aromatase Antibody [NB100-1596] - Detection of aromatase in human fetal temporal lobe lysate using NB 100-1596. ECL exposure, 1-2 minutes.](http://images.novusbio.com/fullsize/Aromatase-Antibody-Western-Blot-NB100-1596-img0003.jpg)
![Immunohistochemistry-Paraffin: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of hypothyroid (Hypo; solid bar; n = 6) rabbits. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of hypothyroid ovaries. Nonlabeling was observed when the primary antibody was omitted. Bars: 100 um (1st image); and 20 um (2nd image). Granulose cells, gc; theca cells, tc. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2017/3795950/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Aromatase-Antibody-Immunohistochemistry-Paraffin-NB100-1596-img0007.jpg)
![Simple Western: Aromatase Antibody [NB100-1596] - Aromatase expression by Western blotting (WES system) from in vitro activated M1 and M2 rat macrophages using Aromatase antibody. Controls include ovary (positive control) and ovary in which the primary antibody was preincubated with an aromatase blocking peptide for 1 h, as well as KGN cells with (positive control) and without (negative control) forskolin treatment. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29898754/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Aromatase Antibody-Simple Western-NB100-1596-img0009.jpg)
![Immunohistochemistry: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) & hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase (a) & Ponceau's Red stained membrane (b). Relative expression of aromatase in C & Hypo groups (c). Data are mean ± SEM. ∗∗P < 0.01. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of control (d, e) & hypothyroid (f, g) ovaries. Nonlabeling was observed when the primary antibody was omitted (negative control; h). Bars: (d) 200 μm; (f) & (h) 100 μm; & (e) & (g) 20 μm. Granulose cells, gc; theca cells, tc. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28133606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1596_rabbit-polyclonal-aromatase-antibody-31020241539251.jpg)
![Immunohistochemistry: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) & hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase (a) & Ponceau's Red stained membrane (b). Relative expression of aromatase in C & Hypo groups (c). Data are mean ± SEM. ∗∗P < 0.01. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of control (d, e) & hypothyroid (f, g) ovaries. Nonlabeling was observed when the primary antibody was omitted (negative control; h). Bars: (d) 200 μm; (f) & (h) 100 μm; & (e) & (g) 20 μm. Granulose cells, gc; theca cells, tc. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28133606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1596_rabbit-polyclonal-aromatase-antibody-310202415392577.jpg)
![Immunohistochemistry: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) & hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase (a) & Ponceau's Red stained membrane (b). Relative expression of aromatase in C & Hypo groups (c). Data are mean ± SEM. ∗∗P < 0.01. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of control (d, e) & hypothyroid (f, g) ovaries. Nonlabeling was observed when the primary antibody was omitted (negative control; h). Bars: (d) 200 μm; (f) & (h) 100 μm; & (e) & (g) 20 μm. Granulose cells, gc; theca cells, tc. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28133606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1596_rabbit-polyclonal-aromatase-antibody-310202415363733.jpg)
![Immunohistochemistry: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) & hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase (a) & Ponceau's Red stained membrane (b). Relative expression of aromatase in C & Hypo groups (c). Data are mean ± SEM. ∗∗P < 0.01. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of control (d, e) & hypothyroid (f, g) ovaries. Nonlabeling was observed when the primary antibody was omitted (negative control; h). Bars: (d) 200 μm; (f) & (h) 100 μm; & (e) & (g) 20 μm. Granulose cells, gc; theca cells, tc. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28133606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1596_rabbit-polyclonal-aromatase-antibody-310202415293319.jpg)
![Immunohistochemistry: Aromatase Antibody [NB100-1596] - Expression of the cytochrome P450 aromatase in the ovary of control (C; open bar; n = 6) & hypothyroid (Hypo; solid bar; n = 6) rabbits. Representative immunoblot showing the expression of aromatase (a) & Ponceau's Red stained membrane (b). Relative expression of aromatase in C & Hypo groups (c). Data are mean ± SEM. ∗∗P < 0.01. Immunoreactivity of antiaromatase (+) was identified in granulosa cells of antral follicles (tertiary, tf; Graafian, gf) of control (d, e) & hypothyroid (f, g) ovaries. Nonlabeling was observed when the primary antibody was omitted (negative control; h). Bars: (d) 200 μm; (f) & (h) 100 μm; & (e) & (g) 20 μm. Granulose cells, gc; theca cells, tc. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28133606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1596_rabbit-polyclonal-aromatase-antibody-310202415382447.jpg)
![Simple Western: Aromatase Antibody [NB100-1596] - Metformin decreases aromatase-positive, tumor-associated macrophages. a Quantification of aromatase-positive cells & b CD68-positive (CD68+) macrophages costaining for aromatase in the tumor border of tissues from control or metformin-treated rats. c Representative control & metformin-treated IHC images of CD68 & aromatase dual staining in tissue bordering mammary tumors (T) (arrows: yellow = CD68+aromatase+, brown = CD68+; scale bar = 50um). d Aromatase expression by Western blotting (WES system) from in vitro activated M1 & M2 rat macrophages using two different primary antibodies (Ab #1: Novus NB100-1596; Ab #2: clone 677, Baylor College of Medicine). Controls include ovary (positive control) & ovary in which the primary antibody was preincubated with an aromatase blocking peptide for 1 h, as well as KGN cells with (positive control) & without (negative control) forskolin treatment. e IHC intensity score for ER & PR (0 = no stain; 1 = weak; 2 = moderate; 3 = strong staining). *p < 0.05 Image collected & cropped by CiteAb from the following publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-0974-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1596_rabbit-polyclonal-aromatase-antibody-31020241682139.jpg)
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0008.jpg "Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).")
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - PTD-p65-P1 peptide inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30 min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0009.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26505) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser276-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26505-img0010.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody [NB110-58872] - Analysis of equal amounts of different tissue and cell lysates using chicken pAb to UCHL1, NB110-58872, dilution 1:2,000 in green, and mouse mAb to Actin, dilution 1:1,000, in red: [1] protein standard, [2] rat brain, [3] mouse brain, [4] NIH-3T3, [5] HEK293, [6] HeLa and [7] SH-SY5Y cells. The single band at 24 kDa mark corresponds to UCHL1 protein which is detectable in CNS extracts and lysates of cells with neuronal properties but not in lysates of HeLa, NIH-3T3 and other non-neuronal cells. Actin is detected with apparent molecular weight of 42 kDa and provides an excellent loading control.](http://images.novusbio.com/fullsize/UCH-L1-PGP9.5-Antibody-Western-Blot-NB110-58872-img0002.jpg "Western Blot: UCH-L1/PGP9.5 Antibody [NB110-58872] - Analysis of equal amounts of different tissue and cell lysates using chicken pAb to UCHL1, NB110-58872, dilution 1:2,000 in green, and mouse mAb to Actin, dilution 1:1,000, in red: [1] protein standard, [2] rat brain, [3] mouse brain, [4] NIH-3T3, [5] HEK293, [6] HeLa and [7] SH-SY5Y cells. The single band at 24 kDa mark corresponds to UCHL1 protein which is detectable in CNS extracts and lysates of cells with neuronal properties but not in lysates of HeLa, NIH-3T3 and other non-neuronal cells. Actin is detected with apparent molecular weight of 42 kDa and provides an excellent loading control.")
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - (A) Immunolabeling of the neuronal marker UCHL1 and TRPV1 in frozen DRG sections and cultured sensory neurons from rat. TRPV1 is selectively expressed in a subpopulation of sensory neurons. (B) Representative view field showing the automated image analysis to quantify TRPV1 expression in cultured sensory neurons. Green encircled objects represent sensory neurons marked by UCHL1. Image collected and cropped by CiteAb from the following publication (journals.plos.org/plosone/article?id=10.1371/journal.pone.0115731), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/UCH-L1-PGP9.5-Antibody-Immunocytochemistry-Immunofluorescence-NB110-58872-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Analysis of cortical neuron-glial cell culture from E20 rat stained with chicken pAb to UCHL1, NB110-58872 , dilution 1:500 in red, and costained with mouse mAb to vimentin, dilution 1:2,000, in green. The blue is DAPI staining of nuclear DNA. The UCHL1 antibody produces strong staining of the cell body and dendrites in neurons. The vimentin antibody stains intermediate filaments in fibroblastic and developing glial cells.](http://images.novusbio.com/fullsize/UCH-L1-PGP9.5-Antibody-Immunocytochemistry-Immunofluorescence-NB110-58872-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-310202416212311.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - PGD2 is a paracrine mediator synthesized in myelinated large-diameter neurons acts on TRPV1(+) neurons.(A) Dose-dependent induction of RII phosphorylation in sensory neurons after 1 min stimulation w/ PGD2 (EC50 = 377 nM, n = 3,>2000 neurons/condition; one-way ANOVA w/ Bonferroni's multiple comparisons test). (B) PGD2 did not induce pRII in non-neuronal cells of same cultures shown in A. (C) Time course of RII phosphorylation indicating long-lasting effects of PGD2 (10 µM) on sensory neurons. (D) Stimulation w/ PGD2 also results in phosphorylation of ERK1/2 measured in same cultures shown in D. (E) Representative experiment demonstrating induction of RII phosphorylation is enhanced in TRPV1(+) neurons (total of 3664 neurons). Plots of respective controls are shown in S2 Fig. (F) Fold changes of pRII intensities in TRPV1(−) (grey bars) & TRPV1(+) (black bars) neurons after 1 min stimulation w/ 10 µM PGD2 (n = 3,>2000 neurons/condition, one-way ANOVA w/ Bonferroni's multiple comparisons test). (G) Co-labeling of TRPV1 & PTGDS revealing PTGDS is expressed in neurons lacking TRPV1 (total of 9951 neurons, also refer to S2 Fig. for control plots). (H) Co-labeling of NF200 & PTGDS showing PTGDS(+) neurons express NF200 (total of 12966 neurons, also refer to S2 Fig. for control plots).(I) Size distribution of PTGDS(+) (green), NF200(+) (red), & all sensory neurons (black) indicating PTGDS(+) neurons are larger than other neurons. (J) Suggested pathway of interneuronal communication between subgroups of sensory neurons. Large-diameter mechanosensitive neurons express PTGDS resulting in production of PGD2, which activates DP1 receptors present on nociceptive neurons expressing TRPV1. Image collected & cropped by CiteAb from following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-31020241621833.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-31020241620379.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-310202416235521.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-31020241623555.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-3102024162498.jpg)
![Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody [NB110-58872] - Validation of the transcriptome data by single cell based quantitative High Content Screening (HCS) microscopy focusing on selected signaling-relevant proteins.(A) Triple staining of the neuronal marker UCHL1 & two different TRPV1 antibodies derived from rabbit & goat, respectively, to facilitate the analysis of various targets. The staining intensities obtained with both TRPV1 antibodies correlated significantly (Spearmans ρ = 0.96, p3000 analyzed neurons per experiment, paired two-tailed t-tests). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0115731), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-58872_chicken-polyclonal-uch-l1-pgp9-5-antibody-310202416235515.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0010.jpg "Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).")
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue 1:300 dilution of rabbit polyclonal Caspase-3 Antibody - (Pro and Active)(NB100-56112), for 1 hour at room temperature followed by anti-rabbit IgG VisUCyte HRP polymer(VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0011.jpg)
![Simple Western: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Simple Western lane view shows a specific band for Caspase 3 in 0.2 mg/ml of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Simple-Western-NB100-56112-img0009.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Effect of acute Cd exposure on BPH1 cell proliferation, Shh signaling activation, and stem cell markers in a time-dependent manner. Cells were incubated with or without 10 uM Cd for the indicated time. Cell lysates were subjected to western blotting using antibodies against p65, Bcl2, BclxL, XIAP, cleaved caspase-3, cleaved PARP, and actin was used as loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-020-0202-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0012.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 expression in formalin-fixed, paraffin-embedded human reactive lymph node using NB100-56112 (Caspase-3 Antibody - (Pro and Active)) at 1:2000. Staining is seen in the apoptosis-prone germinal center B lymphocytes of follicles.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0008.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3 expression in formalin-fixed, paraffin-embedded human breast ductal carcinoma in situ using this antibody at 1:2000. Staining is seen in the the cancerous ducts, but not in the normal lobulus.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0007.jpg)